Stryker (SYK) Stock Price & Analysis
SYK Stock Chart & Stats
- Day’s Range
- EUR 300.40 - EUR 310.80
- 52-Week Range
- EUR 230.50 - EUR 332.40
- Previous Close
- EUR 297.20
- Volume
- N/A
- Average Volume (3M)
- 691
- Market Cap
- EUR 115.34B
- Enterprise Value
- EUR 118.10B
- Total Cash (Recent Filing)
- EUR 3.27B
- Total Debt (Recent Filing)
- EUR 15.43B
- Price to Earnings (P/E)
- 35.5
- Beta
- 0.45
- Next Earnings
- Feb 02, 2027 (Est.)
- EPS Estimate
- 4.47
- Last Dividend Ex-Date
- Sep 30, 2026
- Dividend Yield
- 1.02%
Bulls Say, Bears Say
Bulls Say
Diversified Organic Growth
Growth across both MedSurg and Neurotechnology and Orthopaedics demonstrates a broad revenue base rather than dependence on one product area. This diversification, supported by procedure-driven demand and international expansion, can improve resilience and sustain growth over the next several quarters.
Strong Margins And Cash Generation
High gross and operating margins indicate meaningful profitability from Stryker’s medical technology portfolio, while substantial free cash flow supports product development, acquisitions, debt management and shareholder returns. These economics provide capacity to keep investing through changing procedure environments.
Innovation And Portfolio Expansion
Stryker is extending its competitive position through acquisitions, robotics, AI and a broad pipeline of devices and procedures. New technologies such as FiberLocker and Versius expand the addressable market, while the Mako ecosystem and future launches can deepen customer adoption.
Bears Say
Hip And Knee Market Slowdown
Slower hip and knee procedure growth directly pressures one of Stryker’s important orthopaedic franchises. Affordability concerns, pre-authorization denials and regional softness may constrain volumes for several quarters, reducing the benefit of the company’s established implant and instrument positions.
Peripheral Vascular Supply Disruption
Continuing supply disruption in Peripheral Vascular is limiting the company’s ability to convert demand into sales and can weaken customer availability. Even with sequential improvement, the issue may remain a drag on growth until inventory and product availability normalize fully.
Orthopaedics Execution Pressure
Execution challenges are limiting Stryker’s ability to outperform the orthopaedics market despite its strong franchise and technology portfolio. Delayed visibility, operational distractions and slower new-product adoption could weigh on share gains, growth durability and near-term margin leverage.
SYK FAQ
What was Stryker’s price range in the past 12 months?
What is Stryker’s market cap?
When is Stryker’s upcoming earnings report date?
How were Stryker’s earnings last quarter?
Is Stryker overvalued?
Does Stryker pay dividends?
What is Stryker’s EPS estimate?
How many shares outstanding does Stryker have?
What happened to Stryker’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stryker?
What is the TipRanks Smart Score and how is it calculated?
Stryker Stock Smart Score
Company Description
Stryker
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo
- Employees
- 56,000
- Website
- www.stryker.com
- Address
- 1941 Stryker Way, Portage, MI, 49002, US
Stryker (SYK) Earnings & Revenues
SYK Earnings Call
Earnings Call SentimentNeutral
The call was cautiously constructive but balanced. Stryker reported solid sales growth, adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand, product momentum and a broad innovation and M&A pipeline. However, these positives were offset by a meaningful hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply constraints and reduced full-year guidance. Management expressed confidence in the long-term outlook but acknowledged continued near-term uncertainty.
View all DE:SYK earnings summariesSYK Net sales Breakdown
- 62.30% MedSurg and Neurotechnology
- 37.70% Orthopaedics and Spine
SYK Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 1 | 6 |
| Technical Analysis | 3 | 1 | 6 |
| Moving Averages | 12 | 0 | 0 |
